138 related articles for article (PubMed ID: 9266446)
1. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.
Kramer K; Cheung NK; Humm J; DiResta G; Arbit E; Larson S; Finn R; Rosenblum M; Nguyen H; Gonzalez G; Liu C; Yang YF; Mendelsohn ME; Gillio AP
J Neurooncol; 1997 Nov; 35(2):101-11. PubMed ID: 9266446
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of radioimmunotherapy with intraventricular
Kramer K; Pandit-Taskar N; Humm JL; Zanzonico PB; Haque S; Dunkel IJ; Wolden SL; Donzelli M; Goldman DA; Lewis JS; Lyashchenko SK; Khakoo Y; Carrasquillo JA; Souweidane MM; Greenfield JP; Lyden D; De Braganca KD; Gilheeney SW; Larson SM; Cheung NV
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28940863
[TBL] [Abstract][Full Text] [Related]
4. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
5. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.
Kramer K; Cheung NK; Humm JL; Dantis E; Finn R; Yeh SJ; Antunes NL; Dunkel IJ; Souwedaine M; Larson SM
Med Pediatr Oncol; 2000 Dec; 35(6):716-8. PubMed ID: 11107154
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats.
Bergman I; Pohl CR; Venkataramanan R; Burckart GJ; Stabin M; Barmada MA; Griffin JA; Cheung NK
J Immunother; 1999 Mar; 22(2):114-23. PubMed ID: 10093036
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.
Bergman I; Barmada MA; Heller G; Griffin JA; Cheung NK
Int J Cancer; 1999 Aug; 82(4):538-48. PubMed ID: 10404068
[TBL] [Abstract][Full Text] [Related]
8. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
[TBL] [Abstract][Full Text] [Related]
9. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.
Bergman I; Arbit E; Rosenblum M; Larson SM; Heller G; Cheung NK
J Neurooncol; 1993 Mar; 15(3):235-42. PubMed ID: 8360709
[TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
12. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies.
Papanastassiou V; Pizer BL; Chandler CL; Zananiri TF; Kemshead JT; Hopkins KI
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):541-52. PubMed ID: 7852118
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors.
Fonti R; Cheung NK; Bridger GJ; Guo HF; Abrams MJ; Larson SM
Nucl Med Biol; 1999 Aug; 26(6):681-6. PubMed ID: 10587107
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities.
Yeh SD; Larson SM; Burch L; Kushner BH; Laquaglia M; Finn R; Cheung NK
J Nucl Med; 1991 May; 32(5):769-76. PubMed ID: 1902508
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate.
Heideman RL; McCully C; Balis FM; Poplack DG
Invest New Drugs; 1993; 11(2-3):135-40. PubMed ID: 7505267
[TBL] [Abstract][Full Text] [Related]
17. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
[TBL] [Abstract][Full Text] [Related]
18. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
Cheung NK; Neely JE; Landmeier B; Nelson D; Miraldi F
J Nucl Med; 1987 Oct; 28(10):1577-83. PubMed ID: 3655911
[TBL] [Abstract][Full Text] [Related]
19. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
20. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
